Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

Listen to Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, as they provide their clinical insights into dosing of key later-line treatment options for patients with mCRC.
Kanwal Raghav, MD
person default
Rachel Riechelmann, MD, PhD
Released: October 21, 2021

In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:

  • Individualizing therapy
  • Clinical data and experience informing optimal dosing
  • Key adverse events

Information on this Educational Activity

Faculty

Kanwal Raghav, MD

Associate Professor
GI Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, Texas

Kanwal Raghav, MD, has disclosed that he has received funds for research support from Bayer, Daiichi, Medimmune, Merck, and Roche; consulting fess from Bayer and Daiichi; and fees for non-CME/CE services from Daiichi.
Rachel Riechelmann, MD, PhD

Director, Clinical Oncology
AC Camargo Cancer Center
Sao Paulo, Brazil

Rachel Riechelmann, MD, PhD, has disclosed that she has received funds for research support from Amgen and consulting fees from Amgen, Bayer, MSD, and Novartis.

Program Medium

This program has been made available online.

Acknowledgements

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Expert commentary on potential clinical implications of findings from the MOUNTAINEER trial with tucatinib and trastuzumab in HER2 positive metastatic colorectal cancer, from Clinical Care Options (CCO)

John Strickler, MD Released: August 10, 2022

Nina Beri, MD reviews ongoing clinical trials in targeted therapies for patients with cholangiocarcinoma presented at ASCO 2022, from Clinical Care Options (CCO)

person default Nina Beri, MD Released: August 3, 2022

Downloadable slideset on therapies for previously treated advanced HER2-negative gastric/GEJ cancers, from Clinical Care Options (CCO)

Samuel Klempner, MD Released: July 21, 2022

Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings